This relationship emphasizes the importance of comprehensive serological testing in DM, as the identification of anti-Ro52 antibodies in MDA5-positive patients may help clinicians to predict disease trajectory and to tailor early aggressive immunosuppressive therapies accordingly. The gene discussed is TRIM21; the disease is dermatomyositis.